You are here:

Forthcoming Submission: icatibant (Firazyr)

Indication: Symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency).

Drug Details

Drug Name: icatibant (Firazyr)
Drug Manufacturer: Shire Pharmaceuticals
BNF Category:
Submission type: Abbreviated Submission
SMC Meeting Date: 3/04/2018
Advice Due: 7/05/2018

Back